Jomed chooses to avoid US patent fight with Cordis
This article was originally published in Clinica
Executive Summary
Jomed, a European-based medical technology company which is attempting to launch its Jostent stent graft into the US has made a comprehensive licence agreement with the Cordis division of Johnson & Johnson, covering a number of Cordis' balloon expandable stent patents. Its decision means that Jomed has avoided an expensive and drawn out fight in the US courts.